Compare Hyatt Hotels Corporation (H) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Hyatt Hotels Corporation trades at $190.07 (market cap $17.85B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $89.27M). The key difference: Hyatt Hotels Corporation is far larger — about 200× Inovio Pharmaceuticals Inc's market cap, and Hyatt Hotels Corporation pays a 0.32% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| H | INO | |
|---|---|---|
Market Cap | $17.85B | $89.27M |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $2.87 |
52-Week Low | $135.01 | $1.05 |
Enterprise Value | $21.69B | $60.28M |
Dividend Yield | 0.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $189.75, down 0.47% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $198. Recent earnings show mixed results, with Q2 2026 expected at $0.89 EPS. The company maintains strategic expansions, including new hotel openings and partnerships, while facing profitability challenges with a negative net income margin of -0.48% in 2025.
The stock presents a moderate buy opportunity with analyst support, but risks include declining cash flows and elevated debt. Upside hinges on execution of growth initiatives and improved earnings, while macroeconomic pressures on travel demand pose headwinds. Investors should weigh the 37.5% buy rating against fundamental weaknesses.
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
